Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Abroad (travel likely)Recruiting

Conditions

Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital Fudan university, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Hui Li, PhD) · vincentxwx34@163.com · 13075929630
Study coordinator · 24111210117@m.fudan.edu.cn
Wenxin Xu, PhD (Sub-investigator)
Mincheng Yu, PhD (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Cholangiocarcinoma · Hilar Cholangiocarcinoma · Bile Duct Cancer

Abroad (travel likely)RecruitingPHASE2

Jinan, China

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Bile Duct Cancer · Cholangiocarcinoma · Cholangiocarcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Boston, United States

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Biliary Tract Cancer · Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE1

Baltimore, United States · Baltimore, United States